Selecting Relevant Preclinical Models to Advance ADCs to the Clinic
- Demonstrating a translatable pharmacology approach that links model selection to clinically relevant dosing, integrating toxicity expectations, and literature-based benchmarks to make informed, evidence driven predictions about clinical development
- Spotlighting the criteria for choosing patient representative models including target expression, mutational landscape, prior treatment history, and resistance phenotypes to ensure that preclinical efficacy reflects the biology of anticipated patient populations
- Showcasing how novel payloads are evaluated across tumor models that are sensitive or resistant to standard payloads to support predictions about where novel ADCs could fit into future treatment paradigms and define a clear therapeutic differentiation space